Bloomberg Stock Movers
2026-08-19 · Hosted by — · Bloomberg / iHeartMedia
Executive Summary
Moderna surged more than 40% in pre-market trading — with shares eventually up 50% — after its personalized cancer vaccine, combined with Merck's Keytruda, met both primary and secondary goals in a late-stage melanoma trial, cutting recurrence rates versus immunotherapy alone. Merck shares rose about 5% on the news. Target shares fell roughly 3% despite raising full-year net sales guidance to about 5% growth (from 4%), as the beat was partly fueled by nearly $1 billion in pre-tax tariff refund benefits and followed a 56% year-to-date run-up that had built in high expectations.
Key Stories & Changes
1. Moderna Surges on Cancer Vaccine Breakthrough
Shares up over 40% pre-market, reportedly reaching +50% intraday.
Personalized cancer vaccine combined with Merck's Keytruda met its primary goal, cutting melanoma recurrence versus immunotherapy alone.
Also met a secondary goal, showing potential to prevent tumor spread to new areas of the body.
Merck (MRK) shares rose about 5% on the shared trial success.
2. Target Falls Despite Guidance Raise
Shares down about 3% pre-market despite raising full-year net sales growth guidance to ~5% (from 4%).
Guidance boost includes nearly $1 billion in pre-tax tariff refund benefits — described as a non-recurring item.
Stock has run up 56% year-to-date, versus just 3% for Walmart, raising the bar for the beat to move the stock further.
Company is on track for its first year of net sales growth since 2022, part of a broader turnaround narrative.
3. Lowe's Slips on Guidance Cut
Shares down 2.5% after cutting full-year comparable sales guidance to flat (from up to 2% growth).
Q2 comparable sales rose just 0.2%, missing estimates.
Weakness concentrated in discretionary DIY spending, partly offset by growth in pro, online, and home services.
Contrasts with Home Depot, whose shares were roughly flat after its results the prior day — suggesting the miss is more idiosyncratic to Lowe's.
4. Estee Lauder Beats on Asia Pacific Strength
Shares up over 7% after beating fiscal Q4 top- and bottom-line estimates.
Growth driven largely by Asia Pacific; US off-5% growth measure came in stronger than Wall Street anticipated.
Issued fiscal 2027 EPS guidance pointing to a bottom line above Wall Street expectations.
Trends Identified
1. High Expectations Punish Even Strong Beats
Target's decline despite raised guidance illustrates how a 56% year-to-date rally can set a bar so high that even genuine improvement — inflated in part by one-time tariff refunds — fails to satisfy investors, a dynamic likely to recur as more richly-valued turnaround stories report.
2. Retail Bifurcation by Discretionary vs. Essential Spend
Lowe's guidance cut, driven specifically by weak discretionary DIY spending while pro and services categories held up, mirrors a broader pattern of consumers pulling back on big-ticket, non-essential home spending even as essential and service-based categories remain resilient. ---
Sentiment Analysis
Overall Market Sentiment: Mixed
A batch of consumer and healthcare earnings produced sharply divergent reactions — euphoric for a biotech breakthrough, disappointed for two major retailers despite one technically beating estimates.
Risk Factors Highlighted
Target's reliance on non-recurring tariff refunds: Nearly $1 billion of the guidance raise stems from a one-time benefit, not underlying sales strength.
Elevated retail valuations: Target's 56% year-to-date rally raises the risk of disappointment even on fundamentally solid results.
Discretionary spending softness: Lowe's guidance cut signals consumers are pulling back on non-essential home improvement spending.
Melanoma vaccine trial follow-through: Moderna's stock move assumes continued positive data and eventual regulatory/commercial success not yet realized.
This episode was covered in today's [The Market Signal — 2026-08-19](https://marketsignal.beehiiv.com/p/the-market-signal-2026-08-19), a cross-source synthesis of multiple podcast reports.